Cargando…

Correction to: Amikacin Liposome Inhalation Suspension in Refractory Mycobacterium avium Complex Lung Disease: A Profile of Its Use

Detalles Bibliográficos
Autor principal:	Hoy, Sheridan M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2021
Materias:	Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8195804/ https://www.ncbi.nlm.nih.gov/pubmed/33880719 http://dx.doi.org/10.1007/s40261-021-01036-3

Ejemplares similares

Amikacin Liposome Inhalation Suspension in Refractory Mycobacterium avium Complex Lung Disease: A Profile of Its Use
por: Hoy, Sheridan M.
Publicado: (2021)

Correction to: Amikacin Liposome Inhalation Suspension: A Review in Mycobacterium avium Complex Lung Disease
por: Shirley, Matt
Publicado: (2019)

Amikacin Liposome Inhalation Suspension: A Review in Mycobacterium avium Complex Lung Disease
por: Shirley, Matt
Publicado: (2019)

Amikacin liposome inhalation suspension clinical benefit–risk assessment for refractory Mycobacterium avium complex lung disease
por: Marras, Theodore K., et al.
Publicado: (2022)

805. Amikacin Liposome Inhalation Suspension (ALIS) Add-on Therapy for Refractory Mycobacterium avium Complex (MAC) Lung Disease: Effect of In Vitro Amikacin Susceptibility on Sputum Culture Conversion
por: Brown-Elliott, Barbara A, et al.
Publicado: (2018)

Correction to: Population Pharmacokinetic Evaluation of Amikacin Liposome Inhalation Suspension in Patients with Treatment‑Refractory Nontuberculous Mycobacterial Lung Disease
por: Rubino, Christopher M., et al.
Publicado: (2021)

Amikacin Liposome Inhalation Suspension for Mycobacterium avium Complex Lung Disease: A 12-Month Open-Label Extension Clinical Trial
por: Winthrop, Kevin L., et al.
Publicado: (2021)

Diagnosis and Management of Drug-Induced Interstitial Lung Disease Associated with Amikacin Liposome Inhalation Suspension in Refractory Mycobacterium Avium Complex Pulmonary Disease: A Case Report
por: Hashimoto, Kazuki, et al.
Publicado: (2023)

Early-Phase Adverse Effects and Management of Liposomal Amikacin Inhalation for Refractory Mycobacterium avium Complex Lung Disease in Real-World Settings
por: Morita, Atsuho, et al.
Publicado: (2022)

Amikacin liposome and Mycobacterium avium complex: A systematic review
por: Zangiabadian, Moein, et al.
Publicado: (2022)

Liposomal Amikacin Inhalation Suspension-induced Pneumonitis
por: Kidogawa, Moe, et al.
Publicado: (2022)

Outcomes of Inhaled Amikacin and Clofazimine-Containing Regimens for Treatment of Refractory Mycobacterium avium Complex Pulmonary Disease
por: Kim, Bo-Guen, et al.
Publicado: (2020)

The Use of Amikacin Liposome Inhalation Suspension (Arikayce) in the Treatment of Refractory Nontuberculous Mycobacterial Lung Disease in Adults
por: Khan, Omer, et al.
Publicado: (2020)

Amikacin Liposomal Inhalation Suspension in the Treatment of Mycobacterium abscessus Lung Infection: A French Observational Experience
por: Chiron, Raphael, et al.
Publicado: (2022)

Population Pharmacokinetic Evaluation of Amikacin Liposome Inhalation Suspension in Patients with Treatment-Refractory Nontuberculous Mycobacterial Lung Disease
por: Rubino, Christopher M., et al.
Publicado: (2021)

Safety and Outcomes of Amikacin Liposome Inhalation Suspension for Mycobacterium abscessus Pulmonary Disease: A NTM-NET study
por: Henriette Zweijpfenning, Sanne Maria, et al.
Publicado: (2022)

Amikacin Liposome Inhalation Suspension (ALIS) Penetrates Non-tuberculous Mycobacterial Biofilms and Enhances Amikacin Uptake Into Macrophages
por: Zhang, Jimin, et al.
Publicado: (2018)

Laryngitis after inhalation of liposomal amikacin
por: Morita, Atsuho, et al.
Publicado: (2022)

Positive Effect of Liposomal Amikacin for Inhalation on Mycobacterium abcessus in Cystic Fibrosis Patients
por: Caimmi, Davide, et al.
Publicado: (2018)

Clinical Management of Respiratory Adverse Events Associated With Amikacin Liposome Inhalation Suspension: Results From a Patient Survey
por: Swenson, Colin, et al.
Publicado: (2020)

Comparison of Treatment Outcomes of Cavitary Mycobacterium avium Complex Pulmonary Disease with Streptomycin or Amikacin Use
por: Kim, Seong Min, et al.
Publicado: (2023)

Aerosolized amikacin for treatment of pulmonary Mycobacterium avium infections: an observational case series
por: Davis, Kala K, et al.
Publicado: (2007)

Correction to: Low serum estradiol levels are related to Mycobacterium avium complex lung disease: a cross-sectional study
por: Uwamino, Yoshifumi, et al.
Publicado: (2020)

Association between 16S rRNA gene mutations and susceptibility to amikacin in Mycobacterium avium Complex and Mycobacterium abscessus clinical isolates
por: Kim, Su-Young, et al.
Publicado: (2021)

Sitafloxacin-Containing Regimen for the Treatment of Refractory Mycobacterium avium Complex Lung Disease
por: Asakura, Takanori, et al.
Publicado: (2019)

Impact of initiation of amikacin liposome inhalation suspension on hospitalizations and other healthcare resource utilization measures: a retrospective cohort study in real-world settings
por: Aksamit, Timothy, et al.
Publicado: (2022)

Consolidations in Nodular Bronchiectatic Mycobacterium Avium Complex Lung Disease: Mycobacterium Avium Complex or Other Infection?
por: Im, Soo Ah, et al.
Publicado: (2010)

Pulmonary Deposition and Elimination of Liposomal Amikacin for Inhalation and Effect on Macrophage Function after Administration in Rats
por: Malinin, Vladimir, et al.
Publicado: (2016)

Treatment of severe Mycobacterium avium complex pulmonary disease with adjunctive amikacin and clofazimine versus standard regimen alone: a retrospective study
por: Zweijpfenning, Sanne M.H., et al.
Publicado: (2021)

Correction to: Rozanolixizumab: First Approval
por: Hoy, Sheridan M.
Publicado: (2023)

Correction to: Fremanezumab: First Global Approval
por: Hoy, Sheridan M.
Publicado: (2019)

Adenocarcinoma of the lung with concurrent Mycobacterium avium complex infection
por: Walker, Christopher M, et al.
Publicado: (2021)

Pleuroparenchymal fibroelastosis in mycobacterium avium complex lung disease
por: Sugino, Keishi, et al.
Publicado: (2023)

Treatment Outcome in Patients with Mycobacterium abscessus Complex Lung Disease: The Impact of Tigecycline and Amikacin
por: Yang, Jeng-How, et al.
Publicado: (2022)

Correction: Evolution of the Bovine TLR Gene Family and Member Associations with Mycobacterium avium Subspecies paratuberculosis Infection
por: Fisher, Colleen A., et al.
Publicado: (2012)

Correction: Evolution of the Bovine TLR Gene Family and Member Associations with Mycobacterium avium Subspecies paratuberculosis Infection
por: Fisher, Colleen A., et al.
Publicado: (2012)

Correction: Evolution of the Bovine TLR Gene Family and Member Associations with Mycobacterium avium Subspecies paratuberculosis Infection
por: Fisher, Colleen A., et al.
Publicado: (2012)

Correction to: Sodium Zirconium Cyclosilicate: A Review in Hyperkalaemia
por: Hoy, Sheridan M.
Publicado: (2019)

Correction to: Baricitinib: A Review in Moderate to Severe Atopic Dermatitis
por: Hoy, Sheridan M.
Publicado: (2022)

Correction to: Nusinersen: A Review in 5q Spinal Muscular Atrophy
por: Hoy, Sheridan M.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_it5joi3iked41bah32u3a4bbdu